Gene-Based Therapeutics for Inherited Retinal Diseases
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Inherited retinal diseases (IRDs) are a heterogenous group of orphan eye diseases that typically result from monogenic mutations and are considered attractive targets for gene-based therapeutics. Following the approval of an IRD gene replacement therapy for Leber’s congenital amaurosis due to RPE65 mutations, there has been an intensive international research effort to identify the optimal gene therapy approaches for a range of IRDs and many are now undergoing clinical trials. In this review we explore therapeutic challenges posed by IRDs and review current and future approaches that may be applicable to different subsets of IRD mutations. Emphasis is placed on five distinct approaches to gene-based therapy that have potential to treat the full spectrum of IRDs: 1) gene replacement using adeno-associated virus (AAV) and nonviral delivery vectors, 2) genome editing via the CRISPR/Cas9 system, 3) RNA editing by endogenous and exogenous ADAR, 4) mRNA targeting with antisense oligonucleotides for gene knockdown and splicing modification, and 5) optogenetic approaches that aim to replace the function of native retinal photoreceptors by engineering other retinal cell types to become capable of phototransduction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation
O'Brien, J., Hayder, H., Zayed, Y., & Peng, C. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00402 · Cited by 5,287
Steinmetz, J. D., Bourne, R. R. A., Briant, P. S., Flaxman, S. R., Taylor, H. R. B., Jonas, J. B., Abdoli, A. A., Abrha, W. A., Abualhasan, A., Abu-Gharbieh, E. G., et al. (2021) · The Lancet Global Health · doi:10.1016/s2214-109x(20)30489-7 · Cited by 3,189
Hartong, D. T., Berson, E. L., & Dryja, T. P. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69740-7 · Cited by 2,924 · cited 1×
“Presentation may be delayed depending on the environment, with patients living in well-lit urban settings often presenting later (Hartong et al., 2006).”
BackgroundSafety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145 · cited 1×
“6 kb coding sequence of RPE65 was placed under the control of a modified avian β-actin promoter with a cytomegalovirus enhancer sequence (Maguire et al., 2008; Maguire et al., 2009).”
MethodCRISPR–Cas9 Structures and Mechanisms
Jiang, F., & Doudna, J. A. (2017) · Annual Review of Biophysics · doi:10.1146/annurev-biophys-062215-010822 · Cited by 2,029 · cited 2×
“Human genome editing was originally made possible due to pioneering work in the early 2010’s that demonstrated the use of a clustered regularly interspaced short palindromic repeat (CRISPR) and Cas9 nuclease (CRISPR/Cas9) system derived from Streptococcus pyogenes to introduce site-specific nucleotide alterations in t…”
BackgroundRussell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31868-8 · Cited by 1,952
Intronic microRNA precursors that bypass Drosha processing
Ruby, J. G., Jan, C. H., & Bartel, D. P. (2007) · Nature · doi:10.1038/nature05983 · Cited by 1,722
Dunbar, C. E., High, K. A., Joung, J. K., Kohn, D. B., Ozawa, K., & Sadelain, M. (2018) · Science · doi:10.1126/science.aan4672 · Cited by 1,410 · cited 1×
“From the conception of human gene-based therapeutics in the middle of the last century there has been an increasing expectation by many in the medical and research community that, given a critical mass of knowledge and technology, it will eventually be possible to effectively cure genetic diseases (Miller, 1992; Wirth…”
BackgroundNeural substrates of awakening probed with optogenetic control of hypocretin neurons
Adamantidis, A. R., Zhang, F., Aravanis, A. M., Deisseroth, K., & de Lecea, L. (2007) · Nature · doi:10.1038/nature06310 · Cited by 1,341 · cited 1×
“Optogenetic techniques were originally developed as research tools to explore the function of mammalian neurons in animal models (Adamantidis et al., 2007; Deisseroth, 2011; Zhang et al., 2011).”
MethodSchwartz, S. D., Regillo, C. D., Lam, B. L., Eliott, D., Rosenfeld, P. J., Gregori, N. Z., Hubschman, J.-P., Davis, J. L., Heilwell, G., Spirn, M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61376-3 · Cited by 1,327 · cited 1×
“Standard perimetry has been employed in several trials of IRD therapeutics (Schwartz et al., 2015; Maguire et al., 2019), with loss of central or peripheral field in treated eyes being compared with untreated eyes as a primary or secondary outcome.”
MethodOff-target Effects in CRISPR/Cas9-mediated Genome Engineering
Zhang, X.-H., Tee, L. Y., Wang, X.-G., Huang, Q.-S., & Yang, S.-H. (2015) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2015.37 · Cited by 1,273 · cited 1×
“At present the most important limitation of the CRISPR/ Cas9 system is the introduction of unintended mutations at genomic locations containing sequence homology to the target site, also known as off-target editing (Zhang et al., 2015).”
BackgroundEngineering adeno-associated virus vectors for gene therapy
Li, C., & Samulski, R. J. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-019-0205-4 · Cited by 1,175 · cited 1×
“Work from the early 2000’s demonstrated that AAV serotypes displayed highly variable tropism for different human tissues (Wu et al., 2006; Srivastava, 2016; Li and Samulski, 2020).”
BackgroundSeven-Year Outcomes in Ranibizumab-Treated Patients in ANCHOR, MARINA, and HORIZON
Rofagha, S., Bhisitkul, R. B., Boyer, D. S., Sadda, S. R., & Zhang, K. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.03.046 · Cited by 1,023
Non-syndromic retinitis pigmentosa
Verbakel, S. K., van Huet, R. A. C., Boon, C. J. F., den Hollander, A. I., Collin, R. W. J., Klaver, C. C. W., Hoyng, C. B., Roepman, R., & Klevering, B. J. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.03.005 · Cited by 973
Maguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa, F., Mingozzi, F., Bennicelli, J. L., Ying, G.-S., Rossi, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61836-5 · Cited by 865 · cited 2×
“, 2021b) and showed treatmentdependent improvement in phase 1 trials of RPE65 gene replacement therapy in LCA patients (Maguire et al., 2009).”
BackgroundMethodDalkara, D., Byrne, L. C., Klimczak, R. R., Visel, M., Yin, L., Merigan, W. H., Flannery, J. G., & Schaffer, D. V. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005708 · Cited by 734 · cited 2×
“The use of both in vitro and in vivo directed evolution has been used to dramatically improve the transduction of nonhuman primate photoreceptors following intravitreal delivery of the evolved AAV vectors (Dalkara et al., 2013; Byrne et al., 2020).”
BackgroundDevelopment of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10
Maeder, M. L., Stefanidakis, M., Wilson, C. J., Baral, R., Barrera, L. A., Bounoutas, G. S., Bumcrot, D., Chao, H., Ciulla, D. M., DaSilva, J. A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0327-9 · Cited by 707
Partial recovery of visual function in a blind patient after optogenetic therapy
Sahel, J.-A., Boulanger-Scemama, E., Pagot, C., Arleo, A., Galluppi, F., Martel, J. N., Esposti, S. D., Delaux, A., de Saint Aubert, J.-B., de Montleau, C., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01351-4 · Cited by 700
RPE lipofuscin and its role in retinal pathobiology
Sparrow, J. R., & Boulton, M. (2005) · Experimental Eye Research · doi:10.1016/j.exer.2005.01.007 · Cited by 644
Wirth, T., Parker, N., & Ylä-Herttuala, S. (2013) · Gene · doi:10.1016/j.gene.2013.03.137 · Cited by 607
Cellular uptake and trafficking of antisense oligonucleotides
Crooke, S. T., Wang, S., Vickers, T. A., Shen, W., & Liang, X.-H. (2017) · Nature Biotechnology · doi:10.1038/nbt.3779 · Cited by 582 · cited 1×
“Antisense Oligonucleotides and RNA Interference for Gene Modulation in Inherited Retinal Disease Antisense oligonucleotides (ASOs) are small single-stranded RNA or DNA sequences, typically in the range of 15–30 bases, that can be designed to anneal to specific mRNAs and effect gene silencing, inhibit protein translati…”
BackgroundMaguire, A. M., Russell, S., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., Marshall, K. A., et al. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2019.06.017 · Cited by 409 · cited 1×
“Standard perimetry has been employed in several trials of IRD therapeutics (Schwartz et al., 2015; Maguire et al., 2019), with loss of central or peripheral field in treated eyes being compared with untreated eyes as a primary or secondary outcome.”
MethodWorldwide carrier frequency and genetic prevalence of autosomal recessive inherited retinal diseases
Hanany, M., Rivolta, C., & Sharon, D. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1913179117 · Cited by 408 · cited 2×
“Much of this cost is presumably due to the profound impact that IRDs have on the economic productivity of working-age individuals, where improvements in community eye screening has seen IRDs overtake diabetic retinopathy as the leading cause of blindness among working age adults in some developed nations (Hanany et al…”
BackgroundCremers, F. P. M., Lee, W., Collin, R. W. J., & Allikmets, R. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100861 · Cited by 315
Basic Biology of Adeno-Associated Virus (AAV) Vectors Used in Gene Therapy
Balakrishnan, B., & Jayandharan, G. (2014) · Current Gene Therapy · doi:10.2174/1566523214666140302193709 · Cited by 225 · cited 1×
“AAV is a nonenveloped ssDNA parvovirus with a 25 nm particle size that under normal circumstances depends on co-infection by adenovirus or herpesvirus for replication (Balakrishnan and Jayandharan, 2014).”
BackgroundJacobson, S. G., Acland, G. M., Aguirre, G. D., Aleman, T. S., Schwartz, S. B., Cideciyan, A. V., Zeiss, C. J., Komaromy, A. M., Kaushal, S., Roman, A. J., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.03.005 · Cited by 224
Tsai, Y.-T., Wu, W.-H., Lee, T.-T., Wu, W.-P., Xu, C. L., Park, K. S., Cui, X., Justus, S., Lin, C.-S., Jauregui, R., et al. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2018.04.001 · Cited by 119
Gene therapy for inherited retinal diseases: Progress and possibilities
Hu, M. L., Edwards, T. L., O’Hare, F., Hickey, D. G., Wang, J.-H., Liu, Z., & Ayton, L. N. (2021) · Clinical and Experimental Optometry · doi:10.1080/08164622.2021.1880863 · Cited by 118 · cited 1×
“This, combined with the uniquely favorable features of the human eye, including ease of access, immune-privileged status, and the robust suite of noninvasive functional and structural investigations currently available, has resulted in IRDs being perceived as one of a limited number of ideal targets for the nascent fi…”
BackgroundGalvin, O., Chi, G., Brady, L., Hippert, C., Del Valle Rubido, M., Daly, A., & Michaelides, M. (2020) · Clinical Ophthalmology · doi:10.2147/opth.s241928 · Cited by 116 · cited 2×
“Despite their scarcity, the societal cost of IRDs in the United Kingdom and United States were estimated at more than USD 700 million and USD 30 billion, respectively (Galvin et al., 2020; Gong et al., 2021).”
BackgroundNanoparticle-based technologies for retinal gene therapy
Adijanto, J., & Naash, M. I. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.12.028 · Cited by 107 · cited 1×
“A variety of nanoparticle materials have been developed and contemporary nanoparticles can transfect both RPE and photoreceptors, albeit with less proven durability than that seen after AAV2 transduction with IRD-related genes (Conley and Naash, 2010; Adijanto and Naash, 2015; Trigueros et al., 2019; Sun et al., 2020).”
BackgroundIn vivo–directed evolution of adeno-associated virus in the primate retina
Byrne, L. C., Day, T. P., Visel, M., Strazzeri, J. A., Fortuny, C., Dalkara, D., Merigan, W. H., Schaffer, D. V., & Flannery, J. G. (2020) · JCI Insight · doi:10.1172/jci.insight.135112 · Cited by 104
An AAV Dual Vector Strategy Ameliorates the Stargardt Phenotype in Adult Abca4 −/− Mice
McClements, M. E., Barnard, A. R., Singh, M. S., Charbel Issa, P., Jiang, Z., Radu, R. A., & MacLaren, R. E. (2019) · Human Gene Therapy · doi:10.1089/hum.2018.156 · Cited by 92 · cited 2×
“In vivo efficacy of a dual AAV vector system has previously been demonstrated in a mouse model of Stargardt disease (McClements et al., 2019).”
BackgroundMethodInfluentialEvaluating Efficiencies of Dual AAV Approaches for Retinal Targeting
Carvalho, L. S., Turunen, H. T., Wassmer, S. J., Luna-Velez, M. V., Xiao, R., Bennett, J., & Vandenberghe, L. H. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00503 · Cited by 86 · cited 1×
“Alternatively, a splicing acceptor and splice donor can be added to the termini to enable intermolecular concatamerization and splicing of the two halves into a single contiguous cDNA construct (Carvalho et al., 2017).”
BackgroundGong, J., Cheung, S., Fasso-Opie, A., Galvin, O., Moniz, L. S., Earle, D., Durham, T., Menzo, J., Li, N., Duffy, S., et al. (2021) · Clinical Ophthalmology · doi:10.2147/opth.s313719 · Cited by 64 · cited 2×
“Despite their scarcity, the societal cost of IRDs in the United Kingdom and United States were estimated at more than USD 700 million and USD 30 billion, respectively (Galvin et al., 2020; Gong et al., 2021).”
BackgroundHan, I. C., Cheng, J. L., Burnight, E. R., Ralston, C. L., Fick, J. L., Thomsen, G. J., Tovar, E. F., Russell, S. R., Sohn, E. H., Mullins, R. F., et al. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.043 · Cited by 60 · cited 1×
“…also varied based on the route of delivery, with intravitreal delivery resulting in low transduction efficacy with most serotypes and subretinal and suprachoroidal injection yielding high transduction efficacy only with AAV1 when using a mouse model for transgene delivery (Han et al., 2020).”
BackgroundTherapy Approaches for Stargardt Disease
Piotter, E., McClements, M. E., & MacLaren, R. E. (2021) · Biomolecules · doi:10.3390/biom11081179 · Cited by 49
Teo, K. Y. C., Lee, S. Y., Barathi, A. V., Tun, S. B. B., Tan, L., & Constable, I. J. (2018) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.18-24333 · Cited by 33
Self-citation
Cited by
Gautam, M., Jozic, A., Su, G. L.-N., Herrera-Barrera, M., Curtis, A., Arrizabalaga, S., Tschetter, W., Ryals, R. C., & Sahay, G. (2023) · Nature Communications · doi:10.1038/s41467-023-42189-3 · Cited by 123
RNA-targeting strategies as a platform for ocular gene therapy
Kumar, S., Fry, L. E., Wang, J.-H., Martin, K. R., Hewitt, A. W., Chen, F. K., & Liu, G.-S. (2023) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2022.101110 · Cited by 51
Kovacs, K. D., Ciulla, T. A., & Kiss, S. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2121646 · Cited by 20
Chay, J., Tang, R. W. C., Tan, T.-E., Chan, C. M., Mathur, R., Lee, B. J. H., Chan, H. H., Sim, S. S. K. P., Farooqui, S., Teo, K. Y. C., et al. (2023) · Eye · doi:10.1038/s41433-023-02624-7 · Cited by 15
Self-citationSiles, L., & Pomares, E. (2025) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2025.102482 · Cited by 4
Metadata
- Authors
- Fenner, B. J., Tan, T.-E., Barathi, A. V., Tun, S. B. B., Yeo, S. W., Tsai, A. S. H., Lee, S. Y., Cheung, C. M. G., Chan, C. M., Mehta, J. S., & Teo, K. Y. C.
- Venue
- Frontiers in Genetics
- Publisher
- Frontiers Media SA
- Published
- 2022-01-07
- Volume
- 12
- Pages
- 794805-794805
- ISSN
- 1664-8021 (ISSN-L)
- OpenAlex
- W4205850777
- Cited by
- 59
- References
- 37
- FWCI
- 3.66
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.